A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Abemaciclib|DRUG: Nonsteroidal Aromatase Inhibitor (NSAI)
Sponsor: Eli Lilly and Company